<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01475981</url>
  </required_header>
  <id_info>
    <org_study_id>AK853-U-09-001</org_study_id>
    <nct_id>NCT01475981</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics Study Assessing Ascending Single Oral JTK-853 Doses in Healthy Subjects</brief_title>
  <official_title>Randomized,Double-blind,Placebo-controlled,Ascending Dose Part Evaluating Safety,Tolerability and Pharmacokinetics (PK) of JTK-853 (Fasted/Fed) and Randomized,Open-label,Crossover Part Evaluating Food Effect on PK in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akros Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akros Pharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine the safety, tolerability and pharmacokinetics of
      ascending single oral doses of JTK-853 administered under fasted or fed conditions in healthy
      male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration (Cmax) of JTK-853 and metabolite M2</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach peak or maximum concentration following drug administration (tmax) for JTK-853 and metabolite M2</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from the time of dosing to the last quantifiable time point (AUClast) for JTK-853 and metabolite M2</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from the time of dosing to infinity (AUCinf) for JTK-853 and metabolite M2</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination half-life associated with the terminal slope (Î»z) of a semilogarithmic concentration-time curve (t1/2) for JTK-853 and metabolite M2</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dose 1 JTK-853 (fasted condition)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2 JTK-853 (fasted condition)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3 JTK-853 (fasted condition)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2 JTK-853 (fed condition)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3 JTK-853 (fed condition)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 4 JTK-853 (fed condition)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 5 JTK-853 (fed condition)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 6 JTK-853 (fed condition)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 7 JTK-853 (fed condition)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 5 JTK-853 (high-fat fed condition)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JTK-853 or Placebo</intervention_name>
    <description>Tablets, single dose, fasted, fed or high-fat fed condition</description>
    <arm_group_label>Dose 1 JTK-853 (fasted condition)</arm_group_label>
    <arm_group_label>Dose 2 JTK-853 (fasted condition)</arm_group_label>
    <arm_group_label>Dose 3 JTK-853 (fasted condition)</arm_group_label>
    <arm_group_label>Dose 2 JTK-853 (fed condition)</arm_group_label>
    <arm_group_label>Dose 3 JTK-853 (fed condition)</arm_group_label>
    <arm_group_label>Dose 4 JTK-853 (fed condition)</arm_group_label>
    <arm_group_label>Dose 5 JTK-853 (fed condition)</arm_group_label>
    <arm_group_label>Dose 6 JTK-853 (fed condition)</arm_group_label>
    <arm_group_label>Dose 7 JTK-853 (fed condition)</arm_group_label>
    <arm_group_label>Dose 5 JTK-853 (high-fat fed condition)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Body mass index (BMI) of 18-30 kg/m2 (inclusive)

          2. Non-smokers or subjects who have stopped smoking at least 6 months prior to the
             Screening Visit

        Exclusion Criteria:

          1. History or presence of cardiac disease, including a family history of long-QT syndrome
             or unexplained sudden death

          2. Have used any prescription medication, herbal product, or over-the-counter (OTC)
             medication (except acetaminophen), within 4 weeks prior to the Day before dosing
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shoji Hoshino, D.V.M</last_name>
    <role>Study Director</role>
    <affiliation>Akros Pharma Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PPD, Phase I Clinic</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2011</study_first_submitted>
  <study_first_submitted_qc>November 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2011</study_first_posted>
  <last_update_submitted>November 17, 2011</last_update_submitted>
  <last_update_submitted_qc>November 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>JTK-853</keyword>
  <keyword>single dose</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

